Toxicology – Brodifacoum and Long-Acting Anticoagulants

Core concept

Long-acting anticoagulant rodenticides (LAARs), historically called “superwarfarins,” are potent vitamin K antagonists used as rodenticides.

The characteristic toxicity is:

Delayed vitamin K–dependent coagulopathy → spontaneous bleeding

The most important distinguishing feature is their very prolonged duration of action:

Warfarin → days

Brodifacoum/other LAARs → weeks to months

Therefore, severe poisoning may require high-dose vitamin K₁ for many weeks or months.

Important Agents

Important long-acting anticoagulant rodenticides include:

• Brodifacoum
• Bromadiolone
• Difenacoum
• Difethialone
• Flocoumafen
• Chlorophacinone
• Diphacinone

Historically, the term “superwarfarin” has sometimes been used broadly for anticoagulant rodenticides, although not every anticoagulant rodenticide has the same potency or duration.

LAAR is a more precise clinical term.

Pathophysiology

These agents inhibit vitamin K epoxide reductase (VKOR).

Normally:

Vitamin K epoxide → regenerated active vitamin K → γ-carboxylation of clotting factors

With LAAR poisoning:

VKOR inhibition → failure to regenerate active vitamin K → impaired synthesis of functional vitamin K–dependent proteins

Affected coagulation factors include:

• Factor II
• Factor VII
• Factor IX
• Factor X

Vitamin K–dependent anticoagulant proteins are also affected:

• Protein C
• Protein S
• Protein Z

Why Toxicity Is Delayed

Patients may initially appear completely well because already circulating clotting factors must first be depleted.

Factor VII has a relatively short half-life, so PT/INR becomes abnormal before many other coagulation tests.

Measurable coagulopathy is typically delayed, and clinical bleeding may not appear until several days after exposure. One review found bleeding most commonly occurring approximately 3–9 days after an acute exposure.

This is a major diagnostic pitfall.

Toxic Dose

There is no single reliable toxic dose for all products.

Toxicity depends on:

• Specific anticoagulant
• Concentration of the bait
• Amount ingested
• Acute versus repeated exposure
• Age
• Coingestants
• Baseline anticoagulant therapy

Historical reports suggest that 1–2 mg of brodifacoum can produce anticoagulation in adults.

An evidence-based poison-center guideline suggests that an unintentional ingestion of <1 mg active LAAR ingredient can generally be observed without laboratory testing, whereas asymptomatic exposures of ≥1 mg warrant coagulation testing at approximately 48–72 hours.

The actual active ingredient concentration, rather than the volume of bait alone, is therefore important.

Epidemiology

Most reported exposures are:

• Accidental
• Oral
• In young children

Most small accidental pediatric exposures do not produce clinically important coagulopathy.

Severe poisoning occurs more commonly after:

• Intentional overdose
• Repeated ingestion
• Surreptitious exposure
• Highly concentrated formulations

A review of more than 300,000 reported U.S. exposures found that most were accidental and occurred in children younger than 6 years.

Illicit Drug Contamination

Brodifacoum has also caused large outbreaks after contamination of synthetic cannabinoid products.

During the 2018 U.S. outbreak, patients presented with very high INRs and serious spontaneous bleeding; hematuria was especially common.

Clinical Features

Hematologic

The hallmark is:

Prolonged PT / elevated INR

With severe deficiency:

• aPTT may also become prolonged
• Factors II, VII, IX, and X are reduced

Platelet count and fibrinogen are typically preserved unless another process is occurring.

Bleeding Manifestations

Possible sites include:

HEENT

• Epistaxis
• Gingival bleeding

Dermatologic

• Easy bruising
• Ecchymoses
• Petechiae may occur
• Large hematomas

Genitourinary

Hematuria is particularly common.

Gastrointestinal

• Hematemesis
• Melena
• Hematochezia
• Retroperitoneal hemorrhage

Pulmonary

Rarely:

• Hemoptysis
• Alveolar hemorrhage
• Hemothorax

Musculoskeletal

• Intramuscular hematomas
• Hemarthrosis
• Compartment syndrome from expanding hemorrhage

Reproductive

• Heavy vaginal bleeding
• Menorrhagia

Cardiovascular

Rare but severe:

• Hemopericardium
• Cardiac tamponade

Neurologic

The most feared complication is:

Intracranial hemorrhage

Possible manifestations:

• Severe headache
• Vomiting
• Focal neurologic deficit
• Seizure
• Reduced consciousness
• Coma

Intracranial hemorrhage is an important cause of mortality in severe poisoning.

Hemodynamic Effects

Substantial blood loss may cause:

• Tachycardia
• Hypotension
• Shock

Diagnosis

Think of LAAR poisoning when there is:

Unexplained bleeding + markedly elevated INR + relatively normal platelets/fibrinogen

especially when:

• No therapeutic warfarin use is reported
• Liver disease is absent
• Coagulopathy repeatedly returns after vitamin K treatment

Essential Tests

Obtain:

• PT / INR
• CBC
• Hemoglobin
• Platelets

In significant poisoning also obtain:

• aPTT
• Fibrinogen
• Electrolytes
• BUN
• Creatinine
• Liver-function tests
• Type and screen / crossmatch when bleeding is significant

Coagulation Pattern

Typical LAAR poisoning produces:

↑ PT / INR

and in severe cases:

↑ aPTT

with:

• Normal platelets
• Usually normal fibrinogen

This differentiates it from disorders such as disseminated intravascular coagulation.

Clotting Factor Testing

When the diagnosis is unclear:

• Factors II, VII, IX, and X may be reduced
• Factor V should remain relatively preserved

This distinction can help differentiate vitamin K antagonism from severe hepatic synthetic failure.

Specific LAAR Levels

Brodifacoum and other anticoagulants can be measured using specialized testing, usually LC-MS/MS.

Quantitative testing may:

• Confirm exposure
• Help distinguish covert poisoning
• Help guide duration of vitamin K therapy

However, testing is not rapidly available in many hospitals and should not delay treatment.

Differential Diagnosis

Other causes of prolonged INR or bleeding include:

Toxicologic

• Warfarin
• Other anticoagulants
• Crotalid snake envenomation
• Severe hepatotoxic poisoning

Medical

• Liver failure
• Vitamin K deficiency
• Disseminated intravascular coagulation
• Hemophilia or other factor deficiency
• Acquired factor inhibitors
• Severe malnutrition

A useful clue:

LAAR poisoning → vitamin K–dependent factors low, Factor V preserved

Severe hepatic failure → vitamin K–dependent factors AND Factor V may be reduced

Treatment

1. Resuscitation

Management begins with:

• Airway assessment
• IV access
• Hemodynamic support
• Identification of active bleeding
• Blood-product preparation when necessary

For shock:

• IV isotonic crystalloid as appropriate
• Packed RBC transfusion for clinically significant blood loss

Vitamin K₁ — The Essential Antidotal Therapy

Phytonadione (vitamin K₁) is the key treatment for LAAR-induced coagulopathy.

It allows production of new functional clotting factors despite inhibition of vitamin K recycling.

However:

Vitamin K does not immediately replace already depleted clotting factors.

Therefore, major bleeding requires both vitamin K and rapid factor replacement.

Do Not Give Prophylactic Vitamin K to Patients With a Normal INR

In asymptomatic exposure:

Do not routinely give vitamin K before demonstrating coagulopathy.

Giving vitamin K prophylactically can temporarily normalize or delay INR abnormalities and complicate determination of whether significant poisoning occurred.

Current guidance recommends baseline assessment when indicated and repeat INR approximately 48–72 hours after exposure rather than prophylactic vitamin K.

No Bleeding but Elevated INR

For clinically significant INR elevation without active bleeding:

Oral vitamin K₁ is generally preferred.

One contemporary hospital guideline uses:

Vitamin K₁ 10–20 mg orally when INR is >4 in a patient not taking therapeutic vitamin K antagonists.

However, LAAR poisoning is unusual because very large and prolonged doses may eventually be needed.

Published severe cases frequently require approximately:

50–100 mg/day or more

and reported doses range considerably higher.

There is no universally established optimal dose; therapy should be titrated according to:

• INR
• Clinical bleeding
• Specific LAAR
• Serum LAAR concentration when available
• Toxicology/hematology guidance

Major or Life-Threatening Bleeding

Major hemorrhage requires:

Rapid factor replacement + IV vitamin K₁

Vitamin K₁

A contemporary adult poisoning guideline recommends:

Vitamin K₁ 10 mg IV slowly

for active bleeding due to vitamin K antagonist poisoning.

Subsequent dosing in LAAR poisoning must be individualized because recurrent coagulopathy is common.

Important

IV phytonadione should be administered slowly because hypersensitivity reactions can occur.

Avoid intramuscular injection in a severely coagulopathic patient because of hematoma risk.

Four-Factor Prothrombin Complex Concentrate

For severe or life-threatening bleeding:

4-factor PCC can rapidly replace factors II, VII, IX, and X.

Advantages compared with plasma include:

• Rapid administration
• Small volume
• Rapid INR correction

Direct trials specifically comparing PCC with FFP in LAAR poisoning are lacking, but modern reviews support both for rapid reversal, and evidence from warfarin reversal favors PCC for rapid INR correction.

Fresh Frozen Plasma

If PCC is unavailable or unsuitable:

Fresh frozen plasma (FFP) can replenish vitamin K–dependent clotting factors.

The effect of PCC or FFP is temporary because the LAAR remains in the body.

Therefore:

PCC/FFP must be accompanied by vitamin K₁.

Otherwise coagulopathy will recur.

Why Vitamin K Treatment Lasts So Long

Brodifacoum and related agents are:

• Highly lipophilic
• Strongly retained in tissues/liver
• Slowly eliminated

Reported human brodifacoum elimination half-lives are approximately 15–30 days, with prolonged biological effects.

Consequently:

Vitamin K therapy may be required for weeks to several months.

A 2024 poisoning guideline specifically emphasizes that superwarfarin patients may need vitamin K₁ therapy for several months.

Rebound Coagulopathy

A central principle is:

A normal INR while taking vitamin K does NOT prove that the LAAR has cleared.

Stopping vitamin K too early can cause:

Rebound INR elevation → recurrent spontaneous hemorrhage

One commonly used strategy when specific LAAR levels are unavailable is:

1. Stabilize the patient on oral vitamin K
2. Stop vitamin K when clinically appropriate
3. Repeat PT/INR after approximately 48–72 hours
4. Restart treatment if coagulopathy recurs

Gastrointestinal Decontamination

Do Not Induce Vomiting

The historical recommendation for ipecac is obsolete.

Do not induce vomiting.

Gastric Lavage

Routine gastric lavage is not recommended.

The evidence-based poison-center guideline specifically advises against routine:

• Ipecac
• Gastric lavage

for LAAR exposure.

Activated Charcoal

Activated charcoal may be considered in selected patients after a substantial, very recent intentional ingestion if:

• The airway is intact or protected
• Aspiration risk is low

However, gastrointestinal decontamination is generally not useful after small accidental exposures and should never delay stabilization or transport.

Multiple-Dose Activated Charcoal

Although enterohepatic recirculation has been proposed:

Multiple-dose activated charcoal has not demonstrated reliable clinical benefit and is not routinely recommended.

Cholestyramine

Cholestyramine has been proposed theoretically to interrupt enterohepatic cycling, but evidence is insufficient for routine use.

Hemodialysis

Hemodialysis is generally not useful for removing brodifacoum because these compounds are:

• Highly lipophilic
• Extensively protein/tissue bound
• Associated with a large distribution into tissues

Treatment relies instead on:

• Vitamin K
• Factor replacement
• Supportive care

Monitoring

Acute Exposure

For significant, unknown-dose, deliberate, or chronic exposure:

• Obtain baseline PT/INR
• Repeat PT/INR at approximately 48–72 hours
• Monitor sooner and more frequently if symptoms develop

The 2024 guideline similarly recommends INR at baseline and again approximately 48 hours after ingestion because anticoagulant effects may be delayed.

During Vitamin K Therapy

Monitor:

• PT/INR
• Hemoglobin
• Clinical bleeding
• Renal function when relevant

Severe cases initially require frequent INR testing.

Accidental Pediatric Exposure

Most accidental childhood bait ingestions are small and do not cause clinically important poisoning.

An evidence-based poison-center guideline states:

• <1 mg active ingredient: generally safe for home observation in an asymptomatic accidental exposure
• ≥1 mg or uncertain significant exposure: check coagulation approximately 48–72 hours later

This threshold applies to the amount of active anticoagulant, not grams of bait.

When the product or concentration is unknown, contact a poison center rather than estimating from bait volume alone.

Admission

Hospital admission is indicated for:

• Active bleeding
• Markedly elevated INR
• Hemodynamic instability
• Anemia from hemorrhage
• Intracranial bleeding
• GI or retroperitoneal hemorrhage
• Intentional major ingestion with evolving coagulopathy
• Need for PCC/FFP
• Need for high-dose vitamin K with close monitoring

Severe hemorrhage generally requires ICU-level care.

Disposition

Discharge may be appropriate when:

• Patient is hemodynamically stable
• No active bleeding remains
• Hemoglobin is stable
• A reliable oral vitamin K regimen has been established when required
• Follow-up INR monitoring is guaranteed
• Medication access and adherence are reliable

Intentional exposure also requires appropriate mental-health assessment.

Pregnancy

Maternal coagulopathy can endanger both mother and fetus.

Significant exposure during pregnancy warrants:

• Obstetric consultation
• Maternal INR monitoring
• Assessment for maternal or fetal bleeding when clinically indicated

Human data for individual LAAR agents are limited.

Prognosis

Most small accidental exposures result in no serious complications.

Severe deliberate poisoning can cause:

• Massive hemorrhage
• Intracranial bleeding
• Shock
• Death

However, the anticoagulant effect is highly treatable when recognized and when prolonged vitamin K therapy is maintained.

The most important long-term problem is often recurrent coagulopathy caused by premature discontinuation or poor adherence to vitamin K therapy.

Important Pitfalls

1. Checking INR too early and assuming the patient is safe

The anticoagulant effect is delayed.

A normal initial INR does not exclude significant ingestion.

2. Giving vitamin K prophylactically

Do not routinely give vitamin K when the INR is normal.

It can mask evolving toxicity.

3. Stopping vitamin K when the INR becomes normal

A normal INR while receiving vitamin K does not mean the poison has cleared.

4. Treating major bleeding with vitamin K alone

Vitamin K takes time to restore clotting factors.

Life-threatening bleeding requires:

PCC or FFP + vitamin K₁

5. Treating PCC/FFP as definitive therapy

Factor replacement works only temporarily.

Without ongoing vitamin K, rebound anticoagulation is expected.

6. Missing occult superwarfarin poisoning

Consider LAAR exposure in:

Unexplained bleeding + extremely high INR + normal platelets/fibrinogen

especially when vitamin K correction repeatedly relapses.

7. Missing intracranial bleeding

Severe headache, vomiting, focal deficits, seizure, or reduced consciousness require urgent neuroimaging.

8. Assuming all rat poisons are anticoagulants

Modern rodenticides may instead contain:

• Bromethalin
• Cholecalciferol
• Zinc phosphide
• Other toxicants

The product should be identified whenever possible.

9. Using ipecac or routine gastric lavage

These are obsolete approaches and are not recommended.

High-Yield Toxicology Pearls

Brodifacoum/LAAR poisoning = delayed, prolonged vitamin K antagonist coagulopathy

Think:

Bleeding + very high INR + normal platelets/fibrinogen → consider superwarfarin

Key points:

• Preferred term: long-acting anticoagulant rodenticide (LAAR)
• Mechanism: vitamin K epoxide reductase inhibition
• Factors affected: II, VII, IX, X
• Protein C and S are also affected
• Toxicity is delayed
• Clinical bleeding may appear days after exposure
• Hematuria is a common manifestation
• Intracranial hemorrhage is the most feared complication
• Main laboratory test: PT/INR
• Specific serum LAAR testing can confirm poisoning
• Do not give prophylactic vitamin K when INR is normal
• Elevated INR without bleeding → generally oral vitamin K₁
• Major bleeding → 4-factor PCC or FFP + IV vitamin K₁
• Severe cases often require high-dose vitamin K for weeks to months
• Never stop therapy solely because INR is normal while the patient is still receiving vitamin K
• Recheck INR approximately 48–72 hours after stopping vitamin K
• Routine ipecac, gastric lavage, and multiple-dose charcoal are not recommended
• Hemodialysis does not meaningfully remove brodifacoum
• Most small accidental childhood exposures do well
• Severe intentional poisoning requires prolonged follow-up and meticulous adherence to vitamin K therapy